Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Foshan Miwei Cosmetics Co., Ltd.
WARNING LETTER
•Foshan Miwei Cosmetics Co., Ltd.•October 24, 2025

Foshan Miwei Cosmetics Co., Ltd. – FDA Warning Letter, Oct 24, 2025

Record Details

The FDA issued a Warning Letter to Foshan Miwei Cosmetics Co., Ltd. following an inspection of its manufacturing facility in Guangdong, China, from October 20 to 24, 2025. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations and the Federal Food, Drug, and Cosmetic Act. Key violations included the failure to test finished drug products for strength and microbiological safety before distribution and the lack of identity testing for raw materials. The company also failed to verify the reliability of supplier reports or test for hazardous contaminants in high-risk ingredients. Furthermore, the firm lacked a stability testing program to support its product expiration dates and an adequate Quality Control Unit to oversee operations. The FDA also identified two products, Trust MD SPF 30 Stem Cell Face Cream and inBlair Elevate SPF 15 Moisturizer, as unapproved and misbranded new drugs. These products contained unauthorized active ingredients and featured misleading labeling regarding the function of certain components. As a result of these findings, the FDA placed the firm on an import alert in February 2026. Required actions include hiring an independent consultant to conduct a comprehensive audit, performing retrospective safety testing on products currently on the market, and establishing robust laboratory and quality oversight procedures. The company must provide a detailed remediation plan to the FDA within 15 days to avoid further regulatory action, such as continued refusal of product entry into the United States.

Company
Foshan Miwei Cosmetics Co., Ltd.
Inspection date
October 24, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Tina Smith (Director)
View Company Profile

ID · b1e15995-5841-4cc0-9657-109dba542954

Violation Codes10
21 CFR 201.66(b)(2)FD&C Act 801(a)(3)21 U.S.C. 355hFD&C Act 501(a)(2)(B)21 U.S.C. 331(dd)FD&C Act 201(g)(1)(B)21 U.S.C. 352(a)21 CFR 211FD&C Act 201(p)FD&C Act 502

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Foshan Miwei Cosmetics Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.